vs
Pioneer Bancorp, Inc.（PBFS）与SCYNEXIS INC（SCYX）财务数据对比。点击上方公司名可切换其他公司
Pioneer Bancorp, Inc.的季度营收约是SCYNEXIS INC的1.3倍（$25.0M vs $18.6M），Pioneer Bancorp, Inc.净利率更高（82.1% vs 65.7%，领先16.4%），过去两年SCYNEXIS INC的营收复合增速更高（268.5% vs 144.9%）
先锋银行控股公司（马里兰州）是一家美国银行控股企业，为先锋银行的母公司，主要面向马里兰州本地社区用户提供零售及商业银行服务，涵盖存款账户、住房与商业抵押贷款、消费贷款及小微企业融资等产品。
SCYNEXIS是一家生物科技企业，专注于研发创新抗真菌疗法，用于治疗难治性真菌感染，满足未被覆盖的医疗需求，主要面向医院及专科护理市场，核心产品管线覆盖免疫低下患者等高危人群。
PBFS vs SCYX — 直观对比
营收规模更大
PBFS
是对方的1.3倍
$18.6M
净利率更高
PBFS
高出16.4%
65.7%
两年增速更快
SCYX
近两年复合增速
144.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.0M | $18.6M |
| 净利润 | $3.7M | $12.3M |
| 毛利率 | — | — |
| 营业利润率 | 21.3% | 56.3% |
| 净利率 | 82.1% | 65.7% |
| 营收同比 | — | 1808.5% |
| 净利润同比 | — | 376.5% |
| 每股收益（稀释后） | $0.16 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBFSSCYX
| Q4 25 | $25.0M | $18.6M | ||
| Q3 25 | $24.0M | $334.0K | ||
| Q2 25 | $24.4M | $1.4M | ||
| Q1 25 | $22.8M | $257.0K | ||
| Q4 24 | — | $977.0K | ||
| Q3 24 | $22.0M | $660.0K | ||
| Q2 24 | $20.9M | $736.0K | ||
| Q1 24 | $21.6M | $1.4M |
净利润PBFSSCYX
| Q4 25 | $3.7M | $12.3M | ||
| Q3 25 | $4.3M | $-8.6M | ||
| Q2 25 | $6.5M | $-6.9M | ||
| Q1 25 | $5.8M | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.3M | $-2.8M | ||
| Q2 24 | $3.9M | $-14.5M | ||
| Q1 24 | $4.7M | $411.0K |
营业利润率PBFSSCYX
| Q4 25 | 21.3% | 56.3% | ||
| Q3 25 | 23.4% | -2516.5% | ||
| Q2 25 | 33.3% | -701.0% | ||
| Q1 25 | 32.5% | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 37.2% | -1563.6% | ||
| Q2 24 | 24.1% | -1255.0% | ||
| Q1 24 | 28.1% | -692.5% |
净利率PBFSSCYX
| Q4 25 | 82.1% | 65.7% | ||
| Q3 25 | 18.0% | -2572.2% | ||
| Q2 25 | 26.4% | -504.8% | ||
| Q1 25 | 25.3% | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 28.7% | -425.5% | ||
| Q2 24 | 107.4% | -1964.4% | ||
| Q1 24 | 21.9% | 29.9% |
每股收益（稀释后）PBFSSCYX
| Q4 25 | $0.16 | $0.25 | ||
| Q3 25 | $0.18 | $-0.17 | ||
| Q2 25 | $0.26 | $-0.14 | ||
| Q1 25 | $0.23 | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | $0.25 | $-0.06 | ||
| Q2 24 | $0.15 | $-0.30 | ||
| Q1 24 | $0.19 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $40.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $323.9M | $49.4M |
| 总资产 | $2.2B | $59.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PBFSSCYX
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
股东权益PBFSSCYX
| Q4 25 | $323.9M | $49.4M | ||
| Q3 25 | $314.2M | $36.4M | ||
| Q2 25 | $314.2M | $44.5M | ||
| Q1 25 | $310.7M | $50.5M | ||
| Q4 24 | — | $55.1M | ||
| Q3 24 | $303.8M | $58.5M | ||
| Q2 24 | $296.5M | $60.4M | ||
| Q1 24 | $289.0M | $74.1M |
总资产PBFSSCYX
| Q4 25 | $2.2B | $59.0M | ||
| Q3 25 | $2.2B | $51.1M | ||
| Q2 25 | $2.1B | $60.7M | ||
| Q1 25 | $2.1B | $67.9M | ||
| Q4 24 | — | $90.6M | ||
| Q3 24 | $2.0B | $99.0M | ||
| Q2 24 | — | $107.8M | ||
| Q1 24 | $2.0B | $118.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.1M | $18.4M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 2.97× | 1.50× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PBFSSCYX
| Q4 25 | $11.1M | $18.4M | ||
| Q3 25 | $3.9M | $-8.7M | ||
| Q2 25 | $5.1M | $-7.5M | ||
| Q1 25 | $-3.5M | $-7.5M | ||
| Q4 24 | — | $-24.0M | ||
| Q3 24 | $1.9M | $765.0K | ||
| Q2 24 | $9.0M | $-10.9M | ||
| Q1 24 | $3.3M | $-4.0M |
现金转化率PBFSSCYX
| Q4 25 | 2.97× | 1.50× | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | -0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 2.30× | — | ||
| Q1 24 | 0.70× | -9.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBFS
暂无分部数据
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
